Boston Scientific Unveils Innovative Medical Devices at CIIE, Including ROTAPRO Atherectomy System, WATCHMAN FLX Pro LAA Occluder, Jetstream Plaque Excision System, and ACURATE neo2 Transcatheter Heart Valve

Nov 07, 2023 23:33 CST Updated 23:33

Boston Scientific

Medical Device Manufacturer

Source: Siyu MedTech

Reprint Requirements: Please indicate the source of the article at the beginning of the text, and it can be reprinted directly.

November 6, 2023Boston Scientific, a global leading medical technology company (NYSE:BSX) At the 6th China International Import Expo (hereinafter referred to as“CIIE”) Hosted an innovative product promotion event, focusing on the introduction of five key innovative products in the areas of healthy weight, peripheral vascular health, and cardiac health, and forROTAPRORotational Atherectomy System Series*Held a pre-listing ceremony.

▲ROTAPRORotational Atherectomy System Series*Pre-listing Ceremony

Zhang Jun, President of Boston Scientific Greater China, said:“As a long-time friend of the CIIE, we have successfully launched multiple products in China over the past five years of participation.‘Exhibits Turn into Goods’Today, five products were showcased at the Innovative Products Promotion Conference, further demonstrating our innovative capabilities. I also look forward to these new products and technologies leveraging the CIIE momentum to accelerate the pace of benefiting Chinese patients. In the future, we will continue to bring more cutting-edge medical innovation solutions to meet the unmet needs of a large number of patients in China.”

Striving for Progress, Leading the Course of Innovative Technology

As one of the medical technology companies with the largest global R&D investment, Boston Scientific always adheres to“Innovating for Life”Mission and Vision: Patient-centered, continuously innovating and advancing in the field of minimally invasive interventions to deliver more innovative medical solutions that improve quality of life. At this innovative product promotion event, Boston Scientific showcased several industry-leading products.“Trend Direction”'s brand-new product.

Obesity as defined by the World Health Organization (WHO) recognized chronic diseases, which themselves may also trigger a series of health issues, increasingly加重人们的健康负担. Aiming at this demand, Boston Scientific introduced the world's first product to receiveFDAApproved Single-Balloon Endoscopic Intragastric Weight Loss Product——Orbera Intragastric Balloon*. This product can be introduced into the stomach through the mouth, is nearly non-invasive and reversible. By occupying part of the stomach volume, it reduces the patient's food intake, delays gastric emptying, enhances satiety, and ultimately achieves the goal of weight loss. Data shows that, compared with dieting and exercise alone,OrberaIntragastric balloon can help patients achieve3.1Times of weight loss effect^[1]. It already has20Years of application history, with more than3010,000 Gastric Balloons Worldwide70Used in multiple countries.

OrberaIntragastric Balloon*

With the deepening of China's current population aging, valvular heart disease is becoming increasingly common. Currently, transcatheter aortic valve replacement (TAVR) Has Become the First-Line Treatment for Elderly Patients with Aortic Stenosis^[2]. In order to further contribute toTAVRThe Precision and Efficiency of the Surgery, Protecting Patients with Aortic Stenosis“Gateway to Life”At this innovative product promotion conference, Boston Scientific showcased its star exhibits.——ACURATE neo2 Transcatheter Implantable Heart Valve*. This product is suitable for patients evaluated by the cardiac team as appropriate forTAVRPatients with symptomatic calcified severe aortic stenosis. It utilizes a novel patented technology called Circular Seal, which aims to reduce paravalvular regurgitation after the placement of an artificial aortic valve in the intended position (PVL) of occurrence. At the same time, its delivery system allows for highly precise valve positioning, and the top-down special release mechanism can further support stable release, improving the accuracy of treatment. Clinical research data shows that the success rate of surgeries using this product is as high as98.4%; Postoperative30Day AssessmentPVLLow incidence rate, no patients have experienced severe conditions.PVL^[3]。

ACURATE neo2Transcatheter Implantable Heart Valve*

In the field of peripheral artery disease (PAD) treatment, Boston Scientific has also demonstrated its "unique expertise." To comprehensively address the diverse types of lesions and different kinds of affected areas in peripheral artery disease, Boston Scientific showcased a device at this promotional event — currently the only equipment with active aspiration and perfusion functions, while simultaneously offering plaque removal capabilities for three types of lesions: calcified, plaque, and thrombus.Jetstream Atherectomy System*。This product is equipped with forward cutting blades, an active suction system, and dilation blades, capable of grinding calcified^[4], can remove plaques, and also suction thrombus and debris. It also features differentiated cutting technology that does not damage the blood vessel wall or other soft tissues, offering extremely high safety. This product was successfully included in the National Medical Products Administration’s special review process for innovative medical devices in 2021. We look forward to leveraging the "acceleration effect" of the CIIE to realize its exhibition..."Product Change Commodity".

JetstreamVascular Plaque Rotablation System*

Staying True to Tradition while Innovating, Classic Products Excellently Upgraded

While continuously enriching its product portfolio, Boston Scientific remains committed to perfection, constantly refining its existing classic medical solutions. At this innovative product launch event, Boston Scientific introduced upgraded versions of two classic products in the fields of atrial fibrillation stroke prevention and coronary plaque rotational atherectomy.

Under Boston ScientificWATCHMANLeft Atrial Appendage OccluderA classic product in the field of stroke prevention for atrial fibrillation, and also the first domestically approved left atrial appendage occluder in China, once2018Awarded the honor of being acclaimed as“Nobel Prize in Medicine”The Galen Prize. ItsUpgraded WATCHMAN FLX Left Atrial Appendage Closure Device^[5]Also with the help of“CIIE Effect”, in2022Year3Launched in China in [Month], achieving“Exhibits Turn into Products”'s brilliant transformation. At this promotional conference, Boston Scientific continues to write“Classic Legend”, exhibitedThe All-New WATCHMAN FLX Pro* Left Atrial Appendage Closure Device.This product not only retains the key advantages of the previous generation but also innovatively adopts a special coating design and visual markers, further enhancing the reliability and accuracy of the product. Additionally,WATCHMAN FLX ProAlso increased40mmSize specifications for doctors to utilizeWATCHMANTechnological treatment for a broader patient population.

WATCHMAN FLX ProLeft Atrial Appendage Occluder*

In the field of coronary artery plaque rotational atherectomy, Boston Scientific has also achieved a renewal of its classic technology. The company's exclusive classic product, Rotablator, has been the only rotational atherectomy interventional treatment system in the Chinese market for nearly 30 years and has been applied in tens of thousands of percutaneous coronary intervention (PCI) procedures.Safety and efficacy have been unanimously recognized by clinical practice. At this promotional conference, Boston Scientific showcased its newly upgraded version—ROTAPRORotational AtherectomyProduct Series*. This "new star in rotational atherectomy" has achieved breakthroughs in the lightweight and intelligent design of rotational atherectomy interventional treatment devices. While simplifying the operation and improving surgical efficiency, it also significantly reduces the learning curve and cost for doctors, effectively increasing the utilization rate of coronary plaque rotational atherectomy. As the ROTAPRO series of rotational atherectomy products is pre-launched at the CIIE stage, the product is about to be introduced in China, benefiting a wide range of local patients.

ROTAPRORotational Atherectomy System Series*

*The aforementioned product has not yet been launched in mainland China.

About Boston Scientific

Boston Scientific Corporation is committed to innovation for life. We are dedicated to innovative medical solutions that improve the lives of patients worldwide. For more than four decades, Boston Scientific has consistently led the development of the global medical technology industry by providing a wide range of high-performance medical solutions. These solutions meet critical treatment needs for a broad patient population while reducing healthcare costs.

About Boston Scientific Greater China

Boston Scientific1997Established its China headquarters in Shanghai in the year, with current branches in Beijing, Guangzhou, Chengdu, Hong Kong, and Taipei. The company's core business scope covers interventional cardiology, structural heart disease, cardiac rhythm management, electrophysiology, endoscopic intervention, oncology intervention, peripheral intervention, urology, respiratory intervention, otolaryngology, and neuromodulation. Upholding the tradition of being an innovation leader, Boston Scientific is committed to becoming a respected medical technology company that meets the needs of doctors and patients, demonstrates innovative vitality, and provides high-quality medical products and services for prevention, diagnosis, and treatment.

[1] Orbera® US FDA Pivotal Study.

[2]Structural Heart Disease Professional Committee of the Cardiovascular Physicians Branch of the Chinese Medical Doctor Association.Chinese Expert Consensus on Transcatheter Aortic Valve Replacement(2020Updated Version)[J].Chinese Journal of Interventional Cardiology,2020,28(6):301-309.DOI:10.3969/j.issn.1004-8812.2020.06.001.

[3]Kim WK, et al. Clinical outcomes of the ACURATE neo2 transcatheter heart valve: a prospective, multicenter, observational, post-market surveillance study. EuroIntervention. 2022 Nov 27;19(1):83–92. doi: 10.4244/EIJ-D-22-00914. Epub ahead of print. PMID: 36440588; PMCID: PMC10173758.

[4] EuroIntervention 2015;11:96-103, Jetstream Calcium Study.

[5] China Medical Device Registration20223130126

Editor-in-Chief | Zhao Qing Reviewed by | Yi He Typeset by | Miya